![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: VCAN |
Gene summary for VCAN |
![]() |
Gene information | Species | Human | Gene symbol | VCAN | Gene ID | 1462 |
Gene name | versican | |
Gene Alias | CSPG2 | |
Cytomap | 5q14.2-q14.3 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | P13611 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1462 | VCAN | AEH-subject1 | Human | Endometrium | AEH | 6.82e-04 | -4.39e-01 | -0.3059 |
1462 | VCAN | AEH-subject2 | Human | Endometrium | AEH | 3.70e-19 | -7.02e-01 | -0.2525 |
1462 | VCAN | AEH-subject3 | Human | Endometrium | AEH | 1.97e-08 | -4.97e-01 | -0.2576 |
1462 | VCAN | AEH-subject5 | Human | Endometrium | AEH | 7.03e-13 | -5.88e-01 | -0.2953 |
1462 | VCAN | EEC-subject2 | Human | Endometrium | EEC | 7.87e-17 | -6.81e-01 | -0.2607 |
1462 | VCAN | EEC-subject3 | Human | Endometrium | EEC | 4.38e-11 | -4.27e-01 | -0.2525 |
1462 | VCAN | EEC-subject4 | Human | Endometrium | EEC | 2.31e-16 | -6.39e-01 | -0.2571 |
1462 | VCAN | EEC-subject5 | Human | Endometrium | EEC | 4.33e-15 | -6.61e-01 | -0.249 |
1462 | VCAN | GSM5276935 | Human | Endometrium | EEC | 6.59e-23 | -7.49e-01 | -0.123 |
1462 | VCAN | GSM5276937 | Human | Endometrium | EEC | 1.38e-12 | -6.16e-01 | -0.0897 |
1462 | VCAN | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.79e-19 | -6.46e-01 | -0.1869 |
1462 | VCAN | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 3.53e-14 | -6.49e-01 | -0.1875 |
1462 | VCAN | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 6.30e-24 | -7.76e-01 | -0.1883 |
1462 | VCAN | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.24e-16 | -5.13e-01 | -0.1917 |
1462 | VCAN | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 7.17e-17 | -5.47e-01 | -0.1916 |
1462 | VCAN | P2T-E | Human | Esophagus | ESCC | 3.81e-16 | 5.16e-01 | 0.1177 |
1462 | VCAN | P4T-E | Human | Esophagus | ESCC | 2.19e-11 | 1.09e+00 | 0.1323 |
1462 | VCAN | P5T-E | Human | Esophagus | ESCC | 1.03e-03 | 9.52e-01 | 0.1327 |
1462 | VCAN | P8T-E | Human | Esophagus | ESCC | 2.81e-11 | 7.96e-01 | 0.0889 |
1462 | VCAN | P9T-E | Human | Esophagus | ESCC | 1.52e-13 | 1.37e+00 | 0.1131 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00016498 | Endometrium | AEH | osteoblast differentiation | 52/2100 | 229/18723 | 4.74e-07 | 1.92e-05 | 52 |
GO:00015038 | Endometrium | AEH | ossification | 78/2100 | 408/18723 | 1.54e-06 | 4.85e-05 | 78 |
GO:000164914 | Endometrium | EEC | osteoblast differentiation | 53/2168 | 229/18723 | 5.32e-07 | 2.02e-05 | 53 |
GO:000150313 | Endometrium | EEC | ossification | 79/2168 | 408/18723 | 2.72e-06 | 7.67e-05 | 79 |
GO:000164918 | Esophagus | ESCC | osteoblast differentiation | 140/8552 | 229/18723 | 1.63e-06 | 1.95e-05 | 140 |
GO:000150317 | Esophagus | ESCC | ossification | 232/8552 | 408/18723 | 3.00e-06 | 3.40e-05 | 232 |
GO:000150310 | Oral cavity | OSCC | ossification | 203/7305 | 408/18723 | 5.54e-06 | 6.19e-05 | 203 |
GO:000164910 | Oral cavity | OSCC | osteoblast differentiation | 118/7305 | 229/18723 | 7.51e-05 | 5.85e-04 | 118 |
GO:000150331 | Oral cavity | NEOLP | ossification | 81/2005 | 408/18723 | 2.67e-08 | 1.15e-06 | 81 |
GO:000164931 | Oral cavity | NEOLP | osteoblast differentiation | 47/2005 | 229/18723 | 8.59e-06 | 1.66e-04 | 47 |
GO:00016499 | Prostate | BPH | osteoblast differentiation | 75/3107 | 229/18723 | 1.29e-09 | 5.57e-08 | 75 |
GO:00015039 | Prostate | BPH | ossification | 107/3107 | 408/18723 | 4.31e-07 | 8.83e-06 | 107 |
GO:000164915 | Prostate | Tumor | osteoblast differentiation | 77/3246 | 229/18723 | 1.55e-09 | 7.26e-08 | 77 |
GO:000150314 | Prostate | Tumor | ossification | 109/3246 | 408/18723 | 1.13e-06 | 2.14e-05 | 109 |
GO:000164919 | Skin | AK | osteoblast differentiation | 52/1910 | 229/18723 | 2.27e-08 | 1.28e-06 | 52 |
GO:000150318 | Skin | AK | ossification | 78/1910 | 408/18723 | 3.26e-08 | 1.76e-06 | 78 |
GO:0001649110 | Skin | SCCIS | osteoblast differentiation | 34/919 | 229/18723 | 7.78e-09 | 2.95e-06 | 34 |
GO:000150319 | Skin | SCCIS | ossification | 47/919 | 408/18723 | 5.02e-08 | 8.19e-06 | 47 |
GO:000164923 | Skin | cSCC | osteoblast differentiation | 89/4864 | 229/18723 | 1.18e-05 | 1.51e-04 | 89 |
GO:000150323 | Skin | cSCC | ossification | 137/4864 | 408/18723 | 3.39e-04 | 2.68e-03 | 137 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
VCAN | insertion | Frame_Shift_Ins | novel | c.1993_1994insGCATAAT | p.Val665GlyfsTer21 | p.V665Gfs*21 | P13611 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | ||
VCAN | insertion | Frame_Shift_Ins | novel | c.2692_2693insAGAGGCT | p.Arg898LysfsTer8 | p.R898Kfs*8 | P13611 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | ||
VCAN | insertion | Frame_Shift_Ins | novel | c.3264_3265insTTTTTGTT | p.Val1089PhefsTer5 | p.V1089Ffs*5 | P13611 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | ||
VCAN | insertion | Frame_Shift_Ins | novel | c.5372_5373insTTCCT | p.Val1792SerfsTer10 | p.V1792Sfs*10 | P13611 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | ||
VCAN | insertion | Frame_Shift_Ins | novel | c.6438_6439insTCCTCCTTCTCTACTG | p.Glu2147SerfsTer8 | p.E2147Sfs*8 | P13611 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | ||
VCAN | insertion | In_Frame_Ins | novel | c.7382_7383insGTTAATTTCTGCTGT | p.Ser2461_Asp2462insLeuIleSerAlaVal | p.S2461_D2462insLISAV | P13611 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | ||
VCAN | insertion | Nonsense_Mutation | novel | c.9028_9029insCTTGACCATAGGTTTTGT | p.Ile3010delinsThrTerProTerValLeuLeu | p.I3010delinsT*P*VLL | P13611 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | ||
VCAN | insertion | In_Frame_Ins | novel | c.9193_9194insAGAAGAAAG | p.Thr3065delinsLysLysLysAla | p.T3065delinsKKKA | P13611 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | ||
VCAN | insertion | In_Frame_Ins | novel | c.10084_10085insGGC | p.Tyr3362delinsTrpHis | p.Y3362delinsWH | P13611 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | ||
VCAN | insertion | Frame_Shift_Ins | novel | c.10085_10086insTT | p.Ser3363PhefsTer3 | p.S3363Ffs*3 | P13611 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1462 | VCAN | DRUGGABLE GENOME | CSA | CYCLOSPORINE | 14974815 |
Page: 1 |